Dasatinib plus prednisone as induction and consolidation for adults with Ph‐positive acute lymphoblastic leukaemia: A single‐arm, multicentre, phase 2 trial
British Journal of Haematology · 2023
DOI: 10.1111/bjh.18975 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift British Journal of Haematology, 2023. Verfasst von Mixue Xie und 29 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. Hauptthemen laut MEDLINE: Precursor Cell Lymphoblastic Leukemia-Lymphoma, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 13 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Zhejiang Province.
Abstract (Originalsprache)
To reducing chemotherapy‐related toxicity, the chemo‐free regimens become a new trend of Ph + ALL treatment. Therefore, we conducted a phase 2 trial of dasatinib plus prednisone, as induction (Course I) and early consolidation (Courses II and III) treating newly diagnosed Ph + ALL. The trial was registered at www.chictr.org.cn , ChiCTR2000038053. Forty‐one patients were enrolled from 15 hospitals. The complete remission (CR) was 95% (39/41), including two elderly induction deaths. By the end of Course III, 25.6% (10/39) of patients achieved a complete molecular response. With a median follow‐up of 15.4 months, 2‐year disease‐free survival (DFS) were 100% and 33% for patients who receiving haematopoietic stem cell transplantation (HSCT) at CR1 and receiving chemotherapy alone respectively. When censored at time of HSCT, 2‐year DFS were 51% and 45% for young and elderly patients ( p = 0.987). 2‐year overall survival were 45%, 86% and 100% for patients without HSCT, receiving HSCT after relapse and receiving HSCT at CR1 respectively. A total of 12 patients had marrow recurrences and one had CNS relapse, with 38% occurred early (between Courses I and III). IKZF1 gene deletion was shown to be associated with relapse ( p = 0.019). This chemo‐free induction and early consolidation regimen was efficacious and well‐tolerated in de novo Ph + ALL. Allogeneic HSCT conferred definite survival advantage after chemo‐free induction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
- Department of Hematology, Yinzhou Hospital Affiliated to Medical School of Ningbo University, Ningbo, China.
- Department of Hematology, Ningbo Hospital of Zhejiang University, Ningbo, China.
- Department of Hematology, Ningbo Medical Center Lihuili Hospital, Ningbo, China.
- Department of Hematology, Jinhua Municipal Central Hospital Medical Group, Jinhua, China.
- Department of Hematology, Taizhou Hospital of Zhejiang Province, Taizhou, China.
ORCID-Profile: Xueying Li, Hongyan Tong, Hong-Hu Zhu
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Zhejiang Province
Zitieren
APA
Xie, M., Lu, Y., Ouyang, G., Li, X., Shi, T., Yang, M., Le, J., Hu, H., Zhang, L., Feng, W., Meng, H., Mai, W., Wei, J., Qian, J., Xu, G., Yang, C., Zhou, Lin, Y., Qian, S., …, & Zhu, H. H. (2023). Dasatinib plus prednisone as induction and consolidation for adults with Ph‐positive acute lymphoblastic leukaemia: A single‐arm, multicentre, phase 2 trial. British Journal of Haematology. https://doi.org/10.1111/bjh.18975
Vancouver
Xie M, Lu Y, Ouyang G, Li X, Shi T, Yang M, et al. Dasatinib plus prednisone as induction and consolidation for adults with Ph‐positive acute lymphoblastic leukaemia: A single‐arm, multicentre, phase 2 trial. British Journal of Haematology. 2023. doi:10.1111/bjh.18975
BibTeX
@article{Xie2023,
author = {Xie, Mixue and Lu, Ying and Ouyang, Guifang and Li, Xueying and Shi, Ting and Yang, Min and Le, Jing and Hu, Huixian and Zhang, Li and Feng, Weiying and Meng, Haitao and Mai, Wenyuan and Wei, Juying and Qian, Jiejing and Xu, Gaixiang and Yang, Chunmei and Zhou, De and Lin, Yin and Qian, Suying and Kuang, Yuemin and Zhang, Liming and Zhu, Weiguo and Yao, Guoli and Wu, Gongqiang and Hu, Shao and Huang, Xin and Wang, Yungui and Tong, Hongyan and Jin, Jie and Zhu, Hong-Hu},
title = {Dasatinib plus prednisone as induction and consolidation for adults with Ph‐positive acute lymphoblastic leukaemia: A single‐arm, multicentre, phase 2 trial},
journal = {British Journal of Haematology},
year = {2023},
doi = {10.1111/bjh.18975}
}
EUVIMED